Geographic variation in and the association of neighborhood socioeconomic deprivation with maternal smoking during pregnancy (MSP) (MOR, median odds ratio; IqOR, interquartile odds ratio).

<p>Model 1 was not adjusted for any individual characteristics; Model 2 was adjusted for age and race; Model 3 was adjusted for individual socioeconomic conditions (mom’s education, dad’s education, and household income); Model 4 was adjusted for biological parents’ cohabitation and alcohol use (maternal alcohol use during pregnancy, and maternal history of alcohol dependence); Model 5 was adjusted for all individual covariates.</p

Associations of individual maternal characteristics with maternal smoking during pregnancy (MSP).

<p>Both models were adjusted for neighborhood socioeconomic deprivation.</p

Characteristics of mothers of twins (N = 1658) from the Missouri Adolescent Female Twin Study (MOAFTS).

<p>Characteristics of mothers of twins (N = 1658) from the Missouri Adolescent Female Twin Study (MOAFTS).</p

<i>Post-hoc</i> analyses of <i>CYP2A6</i> SNPs and measures of nicotine dependence^a in treatment-seeking smokers.

<p>^aPairwise correlations of cigarettes per day (continuous) with categorical CPD, TTFC and FTND were 0.914, 0.400 and 0.614, of categorical CPD with TTFC and FTND were 0.379 and 0.622, and of TTFC with FTND were 0.799.</p><p>^bAge, age squared, BMI, sex, education, marital status, three principal components of population genetic variation and site. Descriptive and regression analyses were performed on a sample of 2,418 individuals with called genotypes at both rs4803381 and rs1137115.</p><p><i>Post-hoc</i> analyses of <i>CYP2A6</i> SNPs and measures of nicotine dependence<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126113#t005fn001" target="_blank">^a</a> in treatment-seeking smokers.</p

Clinical trial participant characteristics.

<p>^aContinuous.</p><p>^bFTND/FTCD.</p><p>^cNicotine Replacement Therapy (NRT, NR), Bupropion (BUP, BU), Placebo (PLA, PL), Varenicline (VAR), combined NRT and BUP (NRT+BUP).</p><p>^dEOT ABS = End of treatment seven day point prevalence abstinence, except for trials 00087880 and 00086385 which provided NRT+BUP for 12 weeks and then randomized participants to chronic NRT, chronic BUP or no further treatment.</p><p>^e6MO = Six months.</p><p>Clinical trial participant characteristics.</p